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overall and HCM-related survival in the conservative and invasive
groups. Our Kaplan-Meier analyses supported the findings of our
multivariable models. We believe that these survival curves are a
simple and acceptable method of depicting survival. In our
opinion, plot-predicted values would not provide additive infor-
mation.
In addition, Dr. Collins and colleagues suggest that our Kaplan-
Meier analyses should have used age and not follow-up time (in
years) in depicting survival. We agree that analyzing survival as a
function of age may be appropriate when examining subjects with
either a congenital disorder or with a similar age at onset of the
condition of interest. However, in our study, the age at presenta-
tion to our institution spanned 8 decades (with an average age of
51  16 years), which reflects the heterogeneity of patients in this
cohort. Therefore, we think that plotting age (instead of the
follow-up time) in the Kaplan-Meier survival curves would be
completely noninformative.
We thank Dr. Collins and colleagues for their letter. However,
we believe that the conclusions of our study on the survival of
patients with resting obstructive HCM are valid and will assist
physicians managing patients with this challenging condition.
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Severe Obesity and ST-Segment
Elevation Myocardial Infarction
The Evolving Challenge
Das et al. (1) describe the association of obesity as defined by body
mass index (BMI) with outcomes of ST-segment elevation myo-
cardial infarction (STEMI). The findings of this study need to be
taken in the light of increasing recognition that BMI may not be
a true index of body adiposity (2). This is reflected in a recent studylooking at outcomes of acute coronary syndrome, in which waist
circumference, a marker of visceral obesity, proved to be a more
important discriminator in individuals with a BMI25 kg/m2 (3).
Similarly, use of a lipid accumulation product, a relatively newer
tool for identifying obese individuals, has been shown to be a better
marker of all-cause cardiovascular mortality (4). The investigators
also raise the possibility of “normal BMI representing unmeasured
comorbidities and that overweight and mild obesity likely repre-
senting the more appropriate body mass in the post-MI setting” to
explain the increased prevalence of adverse outcomes in a normal
BMI group. Although interesting, this finding and conclusion
need to be discussed in light of the fact that a BMI30 kg/m2 has
poor sensitivity for detecting true body fat (5,6).
The most important finding of this study was the significantly
higher in-hospital mortality in patients with class III obesity.
Whether this represents an adverse effect of extreme obesity on the
disease (disease effect) or suboptimal treatment strategies (treat-
ment effect) is not clear.
From the disease effect standpoint, this study recognized less
extensive coronary artery disease in class III obesity, but these
individuals may actually have more extensive vulnerable plaque.
This remains speculation, however.
More important, treatment effect is a likely scenario. These
high-risk patients, despite similar use of conventional medications
and reperfusion strategies, may have been underdosed with car-
dioprotective drugs. For example, higher BMI subjects have lower
platelet inhibition by clopidogrel (7). In the current study, clopi-
dogrel was the most commonly used second antiplatelet agent in
addition to aspirin. Along the same lines, Sarno et al. (8) reported
a higher prevalence of stent thrombosis in obese individuals.
Although speculative, these observations make a case for more
aggressive weight-adjusted antiplatelet and other drugs in class III
obese patients with STEMI.
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Reply
We appreciate the interest of Drs. Mehta and Singla in our paper
and the opportunity to respond to the excellent points they raise.
We agree that body mass index (BMI) is an imperfect measure of
adiposity and that other measures of adiposity, such as waist
circumference and body composition analysis, may offer benefits in
understanding the cardiovascular pathophysiology associated with
obesity. At the population level, this distinction may be less
clinically relevant because different measures of adiposity perform
similarly (1). BMI, although imperfect, offers some practical
advantages over other measurements. It is easily understood, is
typically captured as part of routine clinical care by personnel
without specific training and at no added cost, and has been the
most commonly reported measure of obesity, therefore facilitating
comparisons with the existing literature. Numerous studies have
documented an association between increased BMI and incident
cardiovascular disease and death (2,3). In the population of
patients with clinical cardiovascular disease, a high BMI is very
likely to indicate an obese patient. The point made by Drs. Mehta
and Singla that a low BMI is a poorer proxy for the absence of
adiposity in nonobese patients is well taken.
Regarding the implications of the paradoxical increase in risk
that we observed in individuals with a normal BMI that disap-
peared with multivariable adjustment (4), we believe that this is
similar to the signal of increased risk that has previously been seen
among underweight individuals in previous studies (5). Because
obesity predisposes to the development of cardiovascular risk
factors and to incident cardiovascular disease, the ST-segment
elevation myocardial infarction (STEMI) population is more obese
than the general population. It is now uncommon for a normal
weight person to present with STEMI. Our admittedly speculative
comment is simply that those patients with myocardial infarction
(MI) despite normal weight may be hiding occult malefic factors
and that these unrecognized factors may in part drive the pooreroutcomes seen in normal weight versus overweight and mildly
obese patients after MI.
We also concur with their comment that the higher in-hospital
mortality seen in the most obese patients likely represents either an
intrinsic adverse effect of extreme obesity or a deleterious influence
of extreme obesity on treatment patterns or efficacy. We were
reassured to see that the process of care measures were quite similar
for even the most obese patients, which argues against a deleterious
impact of extreme obesity on treatment patterns. We agree that it
is possible that extremely obese patients may have qualitatively or
quantitatively different pathophysiological contributors to risk
compared with less obese individuals and that medication dosing
may be inadequate in the very obese. Clearly, more investigation is
needed in extremely obese individuals to identify the most appro-
priate strategies for treating this rapidly growing segment of the
population.
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